Recent Activity

Loading...

ATAI

ATAI Life Sciences N.V. · NASDAQ

Performance

-11.27%

1W

-20.92%

1M

+9.25%

3M

+60.17%

6M

+34.04%

YTD

-5.5%

1Y

Profile

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Technical Analysis of ATAI 2024-05-10

Overview:

In the last 5 trading days, ATAI stock has shown a mixed performance with fluctuations in price and volume. The technical indicators across trend, momentum, volatility, and volume provide valuable insights into the stock's potential future movements. Let's analyze each category of indicators to determine the possible stock price moveme...

See more ...

Recent News & Updates